[go: up one dir, main page]

WO2000010554A3 - Methods and compositions employing optically pure s(+) vigabatrin - Google Patents

Methods and compositions employing optically pure s(+) vigabatrin Download PDF

Info

Publication number
WO2000010554A3
WO2000010554A3 PCT/US1999/019346 US9919346W WO0010554A3 WO 2000010554 A3 WO2000010554 A3 WO 2000010554A3 US 9919346 W US9919346 W US 9919346W WO 0010554 A3 WO0010554 A3 WO 0010554A3
Authority
WO
WIPO (PCT)
Prior art keywords
vigabatrin
methods
optically pure
compositions employing
employing optically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019346
Other languages
French (fr)
Other versions
WO2000010554A2 (en
Inventor
Paul D Rubin
Timothy J Barberich
William E Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to AU57844/99A priority Critical patent/AU5784499A/en
Priority to EP99945177A priority patent/EP1107748A2/en
Priority to CA002341400A priority patent/CA2341400A1/en
Priority to JP2000565876A priority patent/JP2003520189A/en
Publication of WO2000010554A2 publication Critical patent/WO2000010554A2/en
Publication of WO2000010554A3 publication Critical patent/WO2000010554A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions for the prevention, treatment, and/or management of the symptoms of peripheral neuropathy and related disorders, drug or alcohol addiction or the symptoms thereof, or symptoms associated with drug or alcohol withdrawal, using substantially optically pure S(+) vigabatrin, or a pharmaceutically acceptable salt thereof.
PCT/US1999/019346 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin Ceased WO2000010554A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU57844/99A AU5784499A (en) 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin
EP99945177A EP1107748A2 (en) 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin
CA002341400A CA2341400A1 (en) 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin
JP2000565876A JP2003520189A (en) 1998-08-25 1999-08-24 Methods and compositions using optically pure S (+) vigabatrin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9778698P 1998-08-25 1998-08-25
US60/097,786 1998-08-25
US11445698P 1998-12-30 1998-12-30
US60/114,456 1998-12-30

Publications (2)

Publication Number Publication Date
WO2000010554A2 WO2000010554A2 (en) 2000-03-02
WO2000010554A3 true WO2000010554A3 (en) 2000-11-30

Family

ID=26793638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019346 Ceased WO2000010554A2 (en) 1998-08-25 1999-08-24 Methods and compositions employing optically pure s(+) vigabatrin

Country Status (5)

Country Link
EP (1) EP1107748A2 (en)
JP (1) JP2003520189A (en)
AU (1) AU5784499A (en)
CA (1) CA2341400A1 (en)
WO (1) WO2000010554A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
WO2007136845A2 (en) 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Low-dose doxepin for treatment of sleep disorders in elderly patients
CA2687118A1 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008128115A2 (en) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
CA3016851A1 (en) * 2016-03-10 2017-09-14 Orphelia Pharma Solid dosage forms of vigabatrin
CN110869003A (en) * 2019-01-28 2020-03-06 上海奥科达生物医药科技有限公司 Preservative-free solid-dosage vigabatrin pharmaceutical composition
CN116120200B (en) * 2021-11-15 2025-08-29 武汉武药科技有限公司 Vigabatrin API, vigabatrin solid composition and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US4621145A (en) * 1982-12-30 1986-11-04 Merrell Dow Pharmaceuticals Inc. Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication
WO2000007583A2 (en) * 1998-08-05 2000-02-17 Brookhaven Science Associates Treatment of addiction and addiction-related behavior

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621145A (en) * 1982-12-30 1986-11-04 Merrell Dow Pharmaceuticals Inc. Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication
WO2000007583A2 (en) * 1998-08-05 2000-02-17 Brookhaven Science Associates Treatment of addiction and addiction-related behavior

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALVES N D: "Behavioral-pharmacological study of a possible analgesic effect of vigabatrin (gamma-vinil-GABA) in experimental chronic neuropathic pain", ARQUIVOS DE NEURO-PSIQUIATRIA, (MAR 1998) VOL. 56, NO. 1, PP. 150-150. PUBLISHER: ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA, C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL. ISSN: 0004-282X., vol. 56, no. 1, March 1998 (1998-03-01), UNIV FED CEARA, TESE MESTRADO, FORTALEZA, CEARA, BRAZIL, pages 150, XP000905078 *
BENNETT GJ, XIE JK: "A peripheral mononeuropathy in rats produces disorders of pain sensation like those seen in man", PAIN, vol. 33, 1988, pages 87 - 107, XP000905585 *
BUCKETT W R: "THE INFLUENCE OF A GABA TRANSAMINASE INHIBITOR, GAMMA-VINYL GABA, ON VOLUNTARY MORPHINE CONSUMPTION IN THE RAT", PSYCHOPHARMACOLOGY,DE,SPRINGER VERLAG, BERLIN, vol. 75, no. 2, 1981, pages 214 - 216, XP000856589, ISSN: 0033-3158 *
DEWEY S L ET AL: "A PHARMACOLOGIC STRATEGY FOR THE TREATMENT OF NICOTINE ADDICTION", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 31, no. 1, January 1999 (1999-01-01), pages 76 - 86, XP000856613, ISSN: 0887-4476 *
GRAM L. ET AL: "Experimental studies of the influence of vigabatrin on the GABA system.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, (1989) 27/SUPPL. 1 (13S-17S)., XP000905099 *
MORGAN ET AL: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine", SYNAPSE,GB,WILEY AND SONS, CHICHESTER, vol. 18, no. 1, January 1998 (1998-01-01), pages 60 - 65, XP002127041, ISSN: 0887-4476 *
SASTRE-GARAU P; THOMAS P; BEAUSSART M; GOUDEMAND M: "Manic attack induced by a vigabatrin-clomipramine association.", ENCEPHALE, vol. 19, no. 4, 1993, pages 351 - 352, XP000911788 *
SHERIF FATHI M; TAWATI AHMED M; AHMED SALEEM S; SHARIF SULEIMAN I: "Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase.", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 7, no. 1, 1997, pages 1 - 7, XP000911797 *
STUPPAECK C H ET AL: "THE IRREVERSIBLE GAMMA-AMINOBUTYRATE TRANSAMINASE INHIBITOR VIGABATRIN IN THE TREATMENT OF THE ALCOHOL WITHDRAWAL SYNDROME", ALCOHOL AND ALCOHOLISM. SUPPLEMENT,GB,PERGAMON, OXFORD, vol. 31, no. 1, January 1996 (1996-01-01), pages 109 - 111, XP000856593, ISSN: 1358-6173 *
WEGELIUS K ET AL: "GAMMA-VINYL GABA DECREASES VOLUNTARY ALCOHOL CONSUMPTION IN ALCOHOL-PREFERRING AA RATS", PHARMACOLOGY AND TOXICOLOGY,DK,MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN,, vol. 73, no. 3, September 1993 (1993-09-01), pages 150 - 152, XP000856621, ISSN: 0901-9928 *

Also Published As

Publication number Publication date
AU5784499A (en) 2000-03-14
JP2003520189A (en) 2003-07-02
WO2000010554A2 (en) 2000-03-02
EP1107748A2 (en) 2001-06-20
CA2341400A1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
WO2000016762A3 (en) Method for reducing nicotine dependency
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
WO2001076575A3 (en) The treatment of respiratory diseases
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ZA200202521B (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds.
AU677279B2 (en) Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU3162001A (en) Medicament, a method for its production and the use thereof
AU5489299A (en) Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
WO2003072048A3 (en) Symptomatic relief of gastrointestinal disorders
EP1167354A3 (en) Racemic huperzine A
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
WO1999044608A8 (en) New use
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
WO2000051582A3 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
WO2002011737A3 (en) Anti-inflammatory medicament
WO1997009317A3 (en) Optically active phenyl pyrimidine derivative as analgesic agent
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU2003290015A1 (en) Mastitis treatment
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2260863A1 (en) Treatment of psychotic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2341400

Country of ref document: CA

Ref country code: CA

Ref document number: 2341400

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 57844/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945177

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945177

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999945177

Country of ref document: EP